Form 4: Invivyd CLO Granted 820,000 Stock Options

Invivyd, Inc.'s Chief Legal Officer, Jill Andersen, was granted 820,000 stock options with an exercise price of $1.85, vesting over three years.

Summary

• Jill Andersen, Invivyd, Inc.'s Chief Legal Officer and Secretary, was granted 820,000 stock options.
• The options have an exercise price of $1.85 per share.
• The grant date for these options was January 29, 2026, and they are set to expire on January 28, 2036.
• The options will vest over a three-year period, with 1/36th of the shares vesting in substantially equal monthly installments starting one month after the grant date, contingent on continuous service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive incentive practices and a commitment to long-term executive retention, which can be beneficial for stability and strategic execution.

Positives

• The grant of 820,000 stock options to a key executive like the Chief Legal Officer aligns her incentives with long-term shareholder value creation.
• The three-year vesting schedule promotes executive retention and commitment to the company's sustained performance.

Negatives

• The exercise price of $1.85 is a fixed value, and the options' value is contingent on the stock price exceeding this amount in the future.
• The potential for dilution from the exercise of 820,000 options, while common for executive compensation, could be a minor concern if all options are exercised.

Risks

• The value of the stock options is entirely dependent on Invivyd, Inc.'s stock price appreciating above the $1.85 exercise price. If the stock price does not increase, the options may expire worthless.
• The vesting schedule requires continuous service, meaning the executive must remain with the company for the options to fully vest.

Future Outlook

The stock option grant with a three-year vesting schedule indicates a long-term commitment to the executive and implicitly suggests an expectation of future company growth and stock price appreciation over this period.

Industry Context

StockSavvy.ai notes that granting stock options to key executives is a standard practice in the biotechnology and pharmaceutical industries, including companies like Invivyd, Inc., to attract, retain, and incentivize top talent. This aligns executive interests with long-term shareholder value, a common strategy seen across peers such as Moderna (MRNA) or BioNTech (BNTX) in their compensation structures, albeit with varying scales and specific terms.

Comparison to Industry Standards

• The grant of 820,000 stock options to a Chief Legal Officer is a significant equity award, comparable in scale to grants observed in similar-sized biotech firms for senior executives.
• A three-year vesting period is a common industry standard for executive equity awards, balancing retention incentives with performance alignment, similar to practices at companies like Alnylam Pharmaceuticals (ALNY) or Sarepta Therapeutics (SRPT).
• The exercise price of $1.85, likely the closing price on the grant date, is standard for at-the-money options.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of options, but also potential for increased executive alignment with long-term stock performance.
• Employees: May signal stability in executive leadership and a commitment to retaining key personnel.

Next Steps

• The stock options will begin vesting in monthly installments starting one month after January 29, 2026, over a three-year period.
• Jill Andersen must maintain continuous service with Invivyd, Inc. to fully vest in the options.

Key Dates

Recommendation

This Form 4 filing details a routine executive stock option grant, which is a standard component of compensation and incentive alignment. It does not present new information that would fundamentally alter the investment thesis for Invivyd, Inc. Therefore, a 'hold' recommendation is appropriate, as this event alone is unlikely to drive significant stock price movement or warrant a change in investment strategy.

Keywords

Invivyd, IVVD, Stock Option, Executive Compensation, Form 4, Jill Andersen, Chief Legal Officer, Equity Grant, Vesting